Onconetix (ONCO)
NASDAQ:ONCO
Want to see ONCO full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Revenue Growth Potential
Licensing proprietary technologies to other firms offers a scalable revenue stream, potentially increasing market penetration and financial stability over time.
Negative Factors
High Operating Losses
Significant operating losses reflect inefficiencies and financial strain, challenging the company's ability to achieve profitability and necessitating cost management.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Potential
Licensing proprietary technologies to other firms offers a scalable revenue stream, potentially increasing market penetration and financial stability over time.
Read all positive factors
Onconetix (ONCO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.31M
Dividend YieldN/A
Average Volume (3M)207.81K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue Growth-61.81%
EPS Growth99.68%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.82
Shares Outstanding1,146,457
10 Day Avg. Volume109,373
30 Day Avg. Volume207,813
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)16.24
Price to Sales (P/S)313.95
P/FCF Ratio-26.45
Enterprise Value/Market Cap-2.31
Enterprise Value/Revenue-4.11
Enterprise Value/Gross Profit-5.17
Enterprise Value/Ebitda0.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-200,600
Revenue Forecast (FY)N/A
Onconetix Business Overview & Revenue Model
Company Description
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines fina...
How the Company Makes Money
Onconetix makes money primarily through the sale of its diagnostic assays and therapeutic solutions to healthcare providers, research institutions, and pharmaceutical companies. The company generates revenue by licensing its proprietary technologi...
Onconetix Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 735.20K | 815.37K | 2.52M | 58.47K | 0.00 | 0.00 |
| Gross Profit | 585.43K | 632.91K | 1.06M | -1.13M | -6.75K | -4.89K |
| EBITDA | -6.77M | -13.27M | -57.60M | -36.71M | -13.41M | -3.41M |
| Net Income | -9.70M | -14.03M | -58.69M | -37.41M | -13.42M | -3.42M |
Balance Sheet | ||||||
| Total Assets | 14.83M | 24.93M | 28.18M | 87.52M | 26.31M | 3.08M |
| Cash, Cash Equivalents and Short-Term Investments | 3.72M | 5.22M | 646.50K | 4.55M | 25.75M | 1.93M |
| Total Debt | 289.92K | 48.77K | 9.45M | 9.89M | 0.00 | 0.00 |
| Total Liabilities | 3.08M | 9.16M | 18.57M | 86.11M | 3.92M | 1.64M |
| Stockholders Equity | 11.75M | 15.76M | 9.61M | -5.60M | 22.39M | 1.45M |
Cash Flow | ||||||
| Free Cash Flow | -9.80M | -9.68M | -10.52M | -13.64M | -8.68M | -2.05M |
| Operating Cash Flow | -9.80M | -9.68M | -10.50M | -13.58M | -8.68M | -2.04M |
| Investing Cash Flow | 0.00 | 0.00 | -28.47K | -8.65M | -32.66K | -1.92K |
| Financing Cash Flow | 12.21M | 14.45M | 6.74M | 1.04M | 32.53M | -334.19K |
Onconetix Technical Analysis
Negative
0.74
Price Trends
9.31
Negative
31.90
Negative
85.92
Negative
Market Momentum
-2.48
Negative
23.37
Positive
14.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONCO, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 2.87, below the 50-day MA of 9.31, and below the 200-day MA of 85.92, indicating a bearish trend. The MACD of -2.48 indicates Negative momentum. The RSI at 23.37 is Positive, neither overbought nor oversold. The STOCH value of 14.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ONCO.
Onconetix Risk Analysis
Onconetix disclosed 98 risk factors in its most recent earnings report. Onconetix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Onconetix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.31M | -0.07 | -263.57% | ― | -61.81% | 99.68% | |
| ― | $2.75M | -0.27 | -168.95% | ― | ― | 84.00% | |
46 Neutral | $3.56M | -0.23 | -199.52% | ― | ― | 97.37% | |
41 Neutral | $44.43M | -0.99 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
ONCO
Onconetix
1.14
-321.86
-99.65%
OGEN
Oragenics
0.61
-3.81
-86.28%
KALA
KALA BIO
2.39
-202.11
-98.83%
GRI
GRI Bio
2.01
-35.79
-94.68%
KTTA
Pasithea Therapeutics Corp
0.72
-0.21
-22.28%
Onconetix Corporate Events
Executive/Board ChangesShareholder Meetings
Onconetix Approves CEO Bonus and Stockholder Proposals
Neutral
Dec 10, 2025
On December 5, 2025, Onconetix, Inc. held a meeting where the Compensation Committee approved a $45,000 bonus for Interim CEO Karina Fedasz for her 2025 service, with an additional $5,000 monthly increase in her base compensation starting January ...
Business Operations and StrategyProduct-Related Announcements
Onconetix Amends License Agreement with Labcorp
Neutral
Dec 10, 2025
On December 6, 2025, Proteomedix AG, a subsidiary of Onconetix, Inc., amended its license agreement with Labcorp to conduct a new validation study for Proclarix, a prostate cancer risk identification tool. The amendment stipulates that Labcorp wil...
Shareholder Meetings
Onconetix Announces 2025 Annual Meeting Details
Neutral
Oct 29, 2025
On October 23, 2025, Onconetix, Inc.’s Board of Directors decided to hold the 2025 annual meeting of stockholders on December 5, 2025, at the offices of Ellenoff Grossman Schole LLP in New York. The company announced that shareholder propos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―